Catalyst

Slingshot members are tracking this event:

Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CELG

100%
XLRN

100%

Additional Information

Additional Relevant Details Study DesignData from two Phase 2 studies will be presented at the conference: the completed dose-escalation study in which patients received treatment with luspatercept for three months and the ongoing long-term extension study in which patients receive treatment with luspatercept for up to an additional 24 months. In both the 3-month study and the long-term extension study, red blood cell (RBC) transfusion dependent patients (≥ 4 units RBC / 8 weeks) and non-transfusion dependent patients ( < 4 units RBC / 8 weeks) were enrolled and treated with open-label luspatercept, dosed subcutaneously once every 3 weeks. The primary outcome measure of the base study was the proportion of patients who have an erythroid response, defined as 1) a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of RBC transfusions) in non-transfusion dependent patients, or 2) ≥ 20% reduction in RBC transfusion burden compared to pretreatment in transfusion dependent patients. The primary outcome measure of the long-term extension was the safety and tolerability assessed by adverse events.EfficacyResults in Transfusion Dependent (TD) Beta-Thalassemia Patients   RBC transfusion reduction
over any 12 weeks versus 12
weeks pre-treatment   Response rate (% of patients)   3-month base study(n=30)Long-term extension study(n=24)≥ 20%   80% (24/30)96% (23/24)≥ 33%   67% (20/30)83% (20/24)≥ 50%   53% (16/30)67% (16/24) Durability of Response:In the long-term extension study, the duration of the reduction in transfusion burden of ≥ 33% ranged from 12 to 48+ weeks.Results in Non-Transfusion Dependent (NTD) Beta-Thalassemia Patients   Hemoglobin (Hb) response over
any 12 weeks versus 12
weeks pre-treatment   Response rate (% of patients)in patients treated with ≥ 0.6 mg/kg   3-month base study(n=22)Long-term extension study(n=27)Increase in mean Hb ≥ 1.0 g/dL   64% (14/22)78% (21/27)Increase in mean Hb ≥ 1.5 g/dL   36% (8/22)56% (15/27) Durability of Response:In the long-term extension study, the duration of hemoglobin increase (≥ 1.0 g/dL) ranged from 113 to 505+ days.Improvement in patient-reported quality of life (QoL) measures in NTD patients:
  • Increases in mean hemoglobin over a 12-week period correlated (r=0.67, p=0.001) with increases in
    FACIT-F, a patient-reported outcome (PRO) questionnaire used to assess anemia related symptoms
Safety Results in TD and NTD PatientsTD Patients
  • There were no related serious adverse events and related grade 3 adverse events included: bone pain (n=2 base, n=1 extension), asthenia (n=2 base) and myalgia (n=1 extension)
  • The most common related adverse events (all grades) were bone pain, myalgia, arthralgia, headache, asthenia, and musculoskeletal pain
NTD Patients
  • There were no related serious adverse events and one grade 3 related adverse event of headache (n=1) in the extension study
  • The most common related adverse events were bone pain, headache, musculoskeletal pain and arthralgia
Luspatercept is an investigational product that is not approved for use in any country.The BELIEVE Trial, a global Phase 3 study in regularly transfused beta-thalassemia patients, is currently enrolling.
http://ir.celgene.co...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Beta-thalassemia, Hemoglobin Increase, Luspatercept, Believe Trial, Ntd, Non-transfusion Dependent, Erythroid, Red Blood Cell